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Abstract
Aims: Stents with a passive coating of titanium-nitride-oxide (TiNO) have been compared with Endeavor® 
zotarolimus-eluting stents (E-ZES) with regard to the primary endpoint of in-stent late lumen loss at six to 
eight months. The objective of the present analysis was to compare the long-term outcomes of TiNO stents 
with E-ZES up to five years of clinical follow-up.
Methods and results: A total of 302 patients had been randomly allocated to treatment with TiNO or 
E-ZES. Up to five years of follow-up, major adverse cardiac events (MACE), the composite of cardiac death, 
myocardial infarction, or clinically indicated target vessel revascularisation (TLR), were observed in 27.6% 
of patients treated with TiNO stents and 25.3% of patients treated with E-ZES (RR 1.13, 95% CI: 0.72-1.75, 
p=0.60), with the majority of events related to clinically indicated TVR (TiNO 21.7% versus E-ZES 20.7%, 
RR 1.10, 95% CI: 0.67-1.81). There were no differences with respect to individual events including cardiac 
death, myocardial infarction or stent thrombosis between the two treatment arms up to five years of follow-
up. A majority of patients remained free from angina throughout the entire study duration (TiNO 77.3% ver-
sus E-ZES 76.1%, p=0.92).
Conclusions: Final five-year outcomes of the TIDE trial comparing TiNO stents with E-ZES revealed 
increased rates of MACE driven primarily by clinically indicated TVR. The TIDE trial is registered at 
ClinicalTrials.gov: NCT00492908.
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Introduction
Titanium-nitride-oxide-coated (TiNO) stents have been introduced 
to attenuate the acute inflammatory response to stent-mediated 
arterial injury and promote arterial healing while maintaining the 
antirestenotic efficacy. Passive stent coating with TiNO has been 
shown to decrease platelet adhesion and fibrinogen binding in 
vitro and to reduce neointimal hyperplasia in a porcine restenosis 
model1. In a randomised controlled trial, TiNO stents were superior 
to bare metal stents with regard to late luminal loss at six months 
and major adverse cardiac events (MACE) at six months and five 
years2,3. TiNO stents were associated with a lower cumulative rate 
of MACE at five years of follow-up as compared with paclitaxel-
eluting stents (PES) in a randomised controlled trial of patients with 
acute myocardial infarction4.
In the TIDE trial, powered for a primary angiographic endpoint, 
TiNO stents were inferior to Endeavor® zotarolimus-eluting stents 
(E-ZES; Medtronic, Minneapolis, MN, USA) with regard to late 
loss and binary restenosis5. In the present analysis we present the 
final five-year clinical outcomes of the TIDE trial.
Methods
PATIENT POPULATION
Inclusion criteria of the TIDE trial have been published previously5. 
In summary, patients aged ≥18 years presenting with stable angina 
or unstable angina with at least one lesion with a diameter steno-
sis of ≥50% were eligible for enrolment. All patients gave written 
informed consent for participation in the study, which was approved 
by the local ethics committee. The TIDE trial was an investigator-
initiated study supported by the Inselspital Foundation and per-
formed without industry involvement. The study was registered at 
ClinicalTrials.gov: NCT00492908.
STUDY DESIGN AND PROCEDURES
The design and conduct of the TIDE study, an assessor-blind non-
inferiority trial with a primary angiographic endpoint at six to 
eight months, have been outlined previously5. Patients were ran-
domly assigned to treatment with TiNO stents (Helistent Titan 2; 
Hexacath, Rueil-Malmaison, France) or E-ZES in a 1:1 fashion in 
three institutions in Switzerland.
STUDY ENDPOINTS AND DEFINITIONS
The primary endpoint of the study was in-stent late lumen loss at 
six to eight months after stent implantation as assessed by quantita-
tive coronary angiography and was published previously.
MACE were defined as the composite of cardiac death, myo-
cardial infarction or clinically indicated target vessel revascularisa-
tion (TVR). Follow-up was performed by the use of a standardised 
telephone interview yearly up to five years after intervention.
STATISTICAL ANALYSIS
Baseline clinical characteristics are reported as means and stand-
ard deviations and numbers and percentages as appropriate. 
Cumulative incidences of MACE and clinically indicated target 
Table 1. Clinical outcome at 5 years.
TiNO 
(N=152)  
n (%)
E-ZES 
(N=150)  
n (%)
Mantel-Cox rate 
ratio (RR) 
(95% CI)
log-rank 
p-value
Death 13 (8.6) 8 (5.3) 1.63 (0.67 to 3.93) 0.28
Cardiac death 5 (3.3) 4 (2.7) 1.25 (0.34 to 4.68) 0.74
Myocardial infarction 8 (5.3) 11 (7.3) 0.71 (0.28 to 1.77) 0.46
Q-wave 1 (0.7) 2 (1.3) 0.50 (0.04 to 5.50) 0.56
Non-Q-wave 7 (4.6) 9 (6.0) 0.76 (0.28 to 2.04) 0.58
Clinically indicated TLR 24 (15.8) 19 (12.7) 1.31 (0.71 to 2.40) 0.38
Percutaneous 23 (15.1) 17 (11.3) 1.40 (0.74 to 2.63) 0.29
Surgical 2 (1.3) 2 (1.3) 0.98 (0.14 to 6.98) 0.98
Clinically indicated TVR 33 (21.7) 31 (20.7) 1.10 (0.67 to 1.81) 0.70
Percutaneous 32 (21.1) 28 (18.7) 1.19 (0.72 to 1.99) 0.50
Surgical 3 (2.0) 3 (2.0) 0.98 (0.20 to 4.86) 0.98
Any repeat revascularisation 51 (33.6) 41 (27.3) 1.32 (0.87 to 1.99) 0.19
Percutaneous 49 (32.2) 39 (26.0) 1.33 (0.87 to 2.03) 0.19
Surgical 4 (2.6) 4 (2.7) 0.99 (0.25 to 3.95) 0.98
Cardiac death or MI 12 (7.9) 14 (9.3) 0.84 (0.39 to 1.81) 0.65
Cardiac death, MI, or  
clinically indicated TLR 33 (21.7) 28 (18.7) 1.20 (0.72 to 1.98) 0.49
MACE (cardiac death, MI or 
clinically indicated TVR) 42 (27.6) 38 (25.3) 1.13 (0.72 to 1.75) 0.60
Stroke 3 (2.0) 0 (0.0) 6.91 (0.36 to 132.60)*  0.25*
*Risk ratio with continuity correction of 0.5 and Fisher’s exact test in case of zero events in 
one group.
lesion revascularisation (TLR) up to five years are shown by the 
Kaplan-Meier technique. We used the Mantel-Cox model and the 
corresponding log-rank test for between-group comparison of clini-
cal outcomes occurring up to five years. All patients who underwent 
randomisation were included in the analysis in the group to which 
they were originally allocated (intention-to-treat principle). No 
adjustments were made for multiple comparisons; all p-values and 
95% confidence intervals are two-sided. All analyses were carried 
out using Stata Version 13 (StataCorp, College Station, TX, USA).
Results
A total of 302 patients had been randomly assigned to treatment 
with TiNO stents or E-ZES. Baseline clinical characteristics of the 
two treatment arms were comparable.
Clinical events at five years are summarised in Table 1. There was 
no difference in the rate of MACE between the two groups at five 
years (TiNO 27.6% vs. E-ZES 25.3%, RR 1.13, 95% CI: 0.72-1.75, 
p=0.60). The majority of MACE up to five years occurred within 
the first year of follow-up and were related to clinically indicated 
TVR in a majority of cases (Table 1, Figure 1), driven at least in part 
by protocol-mandated angiographic follow-up. Late events between 
one and five years were attributable to all-cause mortality, and clini-
cally indicated TVR. TLR accounted for the majority of cases with 
clinically indicated TVR and is shown up to five years in Figure 2. 
One case of definite early stent thrombosis occurred in one of the 
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patients treated with TiNO stents. There were no differences with 
respect to any of the individual outcomes between the two treat-
ment arms up to five years of follow-up (Table 1). More than three 
quarters of the patients reported being free of angina at five years of 
follow-up (TiNO 102/152 [77.3%] versus E-ZES 102/150 [76.1%], 
p=0.89). From 97% at year two, adherence to aspirin decreased to 
92% and 95%, respectively, at five years owing to more frequent 
use of clopidogrel (TiNO 11.9% vs. E-ZES 7.3%, p=0.22) (Table 2).
Discussion
The key messages of the final five-year clinical outcome of the ran-
domised comparison between the TiNO stent and the E-ZES are 
the following. 1) There was no significant difference with regard to 
MACE between patients treated with the TiNO stent and the E-ZES 
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Figure 1. Major adverse cardiac events (composite of cardiac death, 
myocardial infarction or clinically indicated target vessel 
revascularisation). Cumulative event curves show the composite 
endpoint of cardiac death, myocardial infarction, and clinically 
indicated target vessel revascularisation up to five years of follow-up 
for TiNO stents and E-ZES.
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Figure 2. Clinically indicated target lesion revascularisation. 
Cumulative event curves show the clinically indicated target lesion 
revascularisations up to five years of follow-up for TiNO stents and 
E-ZES.
Table 2. Medications at 5 years.
TiNO 
(n=135) 
n (%)
ZES 
(n=137) 
n (%)
Fisher’s 
exact 
p-value
Aspirin 124 (91.9) 130 (94.9) 0.22
Clopidogrel 16 (11.9) 10 (7.3) 0.22
Oral anticoagulation 17 (12.6) 8 (5.8) 0.06
Statin 111 (82.2) 120 (87.6) 0.24
Other lipid-lowering drug 2 (1.5) 4 (2.9) 0.68
ACE inhibitor 56 (41.5) 56 (40.9) 1.00
ATII antagonist 39 (28.9) 31 (22.6) 0.27
Beta-blocker 84 (62.2) 88 (64.2) 0.80
Antiarrhythmic drug 7 (5.2) 6 (4.4) 0.78
Ca antagonist 36 (26.7) 29 (21.2) 0.32
Nitrates 0 (0.0) 1 (0.7) 1.00
Diuretic 36 (26.7) 25 (18.2) 0.11
Insulin 10 (7.4) 8 (5.8) 0.63
Oral antidiabetic 20 (14.8) 22 (16.1) 0.87
up to five years of follow-up. 2) The majority of MACE in both 
treatment arms occurred within the first year after intervention and 
were frequently associated with clinically indicated TVR.
The present study has several limitations. First, the trial was pow-
ered for a primary angiographic endpoint and is hence underpow-
ered to evaluate differences between TiNO and E-ZES with regard 
to clinical outcome. Second, protocol-mandated angiographic fol-
low-up at six to eight months increased the rates of revasculari-
sation procedures disproportionately. Third, both stent types have 
been superseded by novel stent technologies with improved safety 
and efficacy profiles. E-ZES has largely been replaced by the 
Endeavor Resolute DES (Medtronic), characterised by delayed and 
more sustained drug elution related to a novel polymer. However, 
the recent publication of the final results of the SORT OUT III trial 
emphasise the importance of long-term clinical outcomes in coro-
nary stent trials to elucidate fully their safety and efficacy profiles6.
The rate of MACE up to five years was considerably higher in the 
TIDE trial (27.6%) as compared to the event rates reported in the 
PORI registry (16.9%)7 and even the TITAX AMI trial4. An “oculo-
stenotic reflex” during the protocol-mandated repeat angiography 
may account for a difference in TLR, along with a high proportion 
of complex patients and longer lesion length compared to previous 
trials. The difference in clinical event rates between the TiNO stent 
and the E-ZES appeared to diminish during the course of the long-
term follow-up.
The present trial was designed in the era of early-generation 
DES when long-term safety of DES had just been raised as a con-
cern. With the introduction of newer-generation DES with high 
antirestenotic efficacy, improved strut endothelialisation, short-
ened minimal duration of dual antiplatelet therapy, and low rates 
of stent thrombosis, the role of passive stent coatings remains to be 
determined. Thin-strut DES releasing antiproliferative agents from 
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biocompatible or biodegradable polymers demonstrated a rate of 
TLR ranging from 2% to 4% in recent trials8,9 and had negligible 
rates of very late ST.
Conclusion
The final five-year outcomes of the TIDE trial comparing TiNO 
stents with E-ZES revealed increased rates of MACE driven pri-
marily by clinically indicated TVR.
Impact on daily practice
Percutaneous coronary intervention with TiNO and E-ZES is 
associated with increased rates of MACE driven primarily by 
clinically indicated TVR. Both devices have been overtaken by 
newer iterations of drug-eluting stents.
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